ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 940

Incidence of Systemic Lupus Erythematosus in England, 1998-2010

Herve Caspard1, Amy Steffey2, Jie Li2 and Trung N. Tran2, 1Epidemiology, Clinical Development, MedImmune LLC, Gaithersburg, MD, 2Epidemiology, Clinical Development, MedImmune, Gaithersburg, MD

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Systemic Lupus Erythematosus (SLE) is a chronic auto-immune disease associated with a wide spectrum of clinical manifestations and increased mortality. The most recent data about incidence of SLE in England date back to 1999.

It has been suggested that the incidence of SLE and other auto-immune diseases has increased over time.

Our purpose was:

* To estimate the incidence of SLE in England from 1998 to 2010 and to describe the incidence rate distribution by demographic factors.

* To discuss the hypothesis that the incidence of SLE increased from 2001 to 2010.

Methods:

We investigated the incidence of SLE among individuals documented in the Clinical Practice Research Datalink (CPRD) and linked with the Hospital Episode Statistics (HES) database. CPRD is a database of anonymized longitudinal medical records from primary care from over 600 practices in the United Kingdom. HES is a database documenting all admissions to the National Health System hospitals in England that can be linked with CPRD since 1997. All individuals documented in GPRD and HES prior to October 1st, 2010 and aged 18 years or older were retained in the analysis.

Patients with SLE were identified as individuals with at least one relevant diagnosis code in CPRD or HES (list of codes available upon request).

Incident cases were defined as patients with at least 12 months of registration in CPRD prior to the date of first diagnosis. Incidence rates were estimated each calendar year from January 1st 1998 to October 1st 2010.

Results:

The incidence rate for the 2001-2010 time period is 5.5 per 100,000 patient*years (table 1): this estimate is very close to the 1998-2000 estimate (5.6 per 100,000 patient*years) and falls within the 95% confidence interval of each calendar year point estimate from 2001 to 2010.

Table 1: Incidence rate estimates per calendar year

Calendar year

Population exposed
(patient*years)

Incident
cases

Incidence rate
(per 100,000 patient*years)

1998-2000

4,213,018

237

5.6
[4.9;6.3]

2001

1,504,620

83

5.1
[4.3;6.7]

2002

1,585,560

89

5.6
[4.4;6.8]

2003

1,639,386

87

5.3
[4.2;6.4]

2004

1,682,720

82

4.9
[3.8;5.9]

2005

1,720,965

88

5.1
[4.0;6.2]

2006

1,768,140

101

5.7
[4.6;6.8]

2007

1,812,779

109

6.0
[4.9;7.1]

2008

1,850,292

111

6.0
[4.9;7.1]

2009

1,859,559

93

5.0
[4.0;6.0]

2010
(through September 30)

1,359,960

79

5.8
[4.5;7.1]

2001-2010

16,784,884

922

5.5
[5.1;5.8]

Incidence rate is higher among women than men: 9.4 versus 1.5 per 100,000 patient*years. It reaches a maximum between 45 and 54 years of age in women (12.2 per 100,000 patient*years) while it keeps growing slightly with age in men; 25%(294) of the incident cases were documented in the HES database only.

Conclusion:

These incidence rates of SLE in England from 1998 to 2010 are consistent with prior estimates and with estimates in other western countries.

We did not observe any significant change in the incidence of SLE in England from 2001 to 2010.


Disclosure:

H. Caspard,
None;

A. Steffey,
None;

J. Li,
None;

T. N. Tran,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-of-systemic-lupus-erythematosus-in-england-1998-2010/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology